异动解读 | 业绩大幅下滑,昭衍新药盘中大跌8.55%

异动解读
31 Mar

周一盘中,昭衍新药(06127.HK)股价大跌8.55%,引发市场关注。这一显著跌幅主要源于公司发布的年度业绩报告不及预期。

根据昭衍新药最新公布的财务报告,截至去年12月底,公司全年营业额为20.18亿元人民币,同比下降15.1%。更令投资者失望的是,公司纯利大幅下滑至7,407.5万元人民币,同比骤降81.3%。每股盈利降至0.1元人民币,相比之下去年同期为0.53元人民币。

值得注意的是,公司宣布派发末期息0.03元人民币,较上年同期的0.16元人民币大幅缩减。这一系列数据显示公司经营状况出现明显恶化,直接导致投资者信心受挫,引发了股价的显著下跌。分析人士指出,昭衍新药面临的经营压力可能持续一段时间,建议投资者密切关注公司后续的经营策略调整和市场反应。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10